tetano
Editor, Senior Moderator
Nature
. 2023 Jan 16.
doi: 10.1038/s41586-023-05715-3. Online ahead of print.
Molecular fate-mapping of serum antibody responses to repeat immunization
Ariën Schiepers[SUP] 1 [/SUP], Marije F L van 't Wout[SUP] 1 [/SUP], Allison J Greaney[SUP] 2 [/SUP], Trinity Zang[SUP] 3 [/SUP], Hiromi Muramatsu[SUP] 4 [/SUP], Paulo J C Lin[SUP] 5 [/SUP], Ying K Tam[SUP] 5 [/SUP], Luka Mesin[SUP] 1 [/SUP], Tyler N Starr[SUP] 2 [/SUP], Paul D Bieniasz[SUP] 3 6 [/SUP], Norbert Pardi[SUP] 4 [/SUP], Jesse D Bloom[SUP] 2 6 [/SUP], Gabriel D Victora[SUP] 7 [/SUP]
Affiliations
Abstract
The protective efficacy of serum antibody results from the interplay of antigen-specific B cell clones of different affinities and specificities. These cellular dynamics underlie serum-level phenomena such as "Original Antigenic Sin" (OAS), a proposed propensity of the immune system to rely repeatedly on the first cohort of B cells engaged by an antigenic stimulus when encountering related antigens, in detriment of inducing de novo responses[SUP]1-5[/SUP]. OAS-type suppression of new, variant-specific antibodies may pose a barrier to vaccination against rapidly evolving viruses such as influenza and SARS-CoV-2[SUP]6,7[/SUP]. Precise measurement of OAS-type suppression is challenging because cellular and temporal origins cannot readily be ascribed to antibodies in circulation; thus, its impact on subsequent antibody responses remains unclear[SUP]5,8[/SUP]. Here, we introduce a molecular fate-mapping approach in which serum antibodies derived from specific cohorts of B cells can be differentially detected. We show that serum responses to sequential homologous boosting derive overwhelmingly from primary cohort B cells, while later induction of new antibody responses from naïve B cells is strongly suppressed. Such "primary addiction" decreases sharply as a function of antigenic distance, allowing reimmunization with divergent viral glycoproteins to produce de novo antibody responses targeting epitopes absent from the priming variant. Our findings have implications for the understanding of OAS and for the design and testing of vaccines against evolving pathogens.
. 2023 Jan 16.
doi: 10.1038/s41586-023-05715-3. Online ahead of print.
Molecular fate-mapping of serum antibody responses to repeat immunization
Ariën Schiepers[SUP] 1 [/SUP], Marije F L van 't Wout[SUP] 1 [/SUP], Allison J Greaney[SUP] 2 [/SUP], Trinity Zang[SUP] 3 [/SUP], Hiromi Muramatsu[SUP] 4 [/SUP], Paulo J C Lin[SUP] 5 [/SUP], Ying K Tam[SUP] 5 [/SUP], Luka Mesin[SUP] 1 [/SUP], Tyler N Starr[SUP] 2 [/SUP], Paul D Bieniasz[SUP] 3 6 [/SUP], Norbert Pardi[SUP] 4 [/SUP], Jesse D Bloom[SUP] 2 6 [/SUP], Gabriel D Victora[SUP] 7 [/SUP]
Affiliations
- PMID: 36646114
- DOI: 10.1038/s41586-023-05715-3
Abstract
The protective efficacy of serum antibody results from the interplay of antigen-specific B cell clones of different affinities and specificities. These cellular dynamics underlie serum-level phenomena such as "Original Antigenic Sin" (OAS), a proposed propensity of the immune system to rely repeatedly on the first cohort of B cells engaged by an antigenic stimulus when encountering related antigens, in detriment of inducing de novo responses[SUP]1-5[/SUP]. OAS-type suppression of new, variant-specific antibodies may pose a barrier to vaccination against rapidly evolving viruses such as influenza and SARS-CoV-2[SUP]6,7[/SUP]. Precise measurement of OAS-type suppression is challenging because cellular and temporal origins cannot readily be ascribed to antibodies in circulation; thus, its impact on subsequent antibody responses remains unclear[SUP]5,8[/SUP]. Here, we introduce a molecular fate-mapping approach in which serum antibodies derived from specific cohorts of B cells can be differentially detected. We show that serum responses to sequential homologous boosting derive overwhelmingly from primary cohort B cells, while later induction of new antibody responses from naïve B cells is strongly suppressed. Such "primary addiction" decreases sharply as a function of antigenic distance, allowing reimmunization with divergent viral glycoproteins to produce de novo antibody responses targeting epitopes absent from the priming variant. Our findings have implications for the understanding of OAS and for the design and testing of vaccines against evolving pathogens.